Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 2/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815726 | 0.81 | TDP1 (0.63) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL1039253 | 0.81 | TDP1 (0.63) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL3966477 | 0.80 | TDP1 (0.73) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL1306628 | 0.79 | TDP1 (0.59) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL30564238 | 0.78 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL6794361 | 0.78 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL6442808 | 0.78 | TDP1 (1.00) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL28148842 | 0.77 | SMN1; SMN2 (0.56) | TDP1HTTSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL5913820 | 0.77 | TDP1 (0.81) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL23706470 | 0.75 | TDP1 (0.64) | TDP1CYP11B1CYP11B2TNFEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6277838-B1 | ADMINISTERING DOSAGE OF ANXIOLYTIC AGENT TO ANIMAL | COCENSYS, INC. | 2001-08-21 | — | — | US | claimed |
| EP-0752860-B1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | EURO CELTIQUE SA (LU) | 2000-08-23 | — | — | EP | claimed |
| EP-0752860-A4 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0752860-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1997-01-15 | — | — | EP | claimed |
| WO-1995021617-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1995-08-17 | — | — | WO | claimed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | TDP1 4405/4885CYP11B1 1303/4885CYP11B2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.